MedTrace Logo

Safety, Tolerance and Immunogenicity of EuCorVac-19 for the Prevention of COVID-19 in Healthy Adults

NCT04783311 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 279

Last updated 2023-05-19

No results posted yet for this study

Summary

Phase I/II study to determine safety, tolerance and immunogenicity of EuCorVac-19, a recombinant protein vaccine, for the prevention of COVID-19 in healthy adults

Conditions

Interventions

BIOLOGICAL

EuCorVac-19

Two intramuscular doses (0.5mL per dose) at 3-week interval

OTHER

Normal Saline

Two intramuscular doses (0.5mL per dose) at 3-week interval

Sponsors & Collaborators

  • EuBiologics Co.,Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-02-23
Primary Completion
2021-10-15
Completion
2022-09-27

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04783311 on ClinicalTrials.gov